Having trouble accessing articles? Reset your cache.

Next up for GlycoMimetics after tanking in sickle cell disease

Despite plunging 69% to $2.80 on Monday after the Phase III miss of sickle cell disease candidate rivipansel, GlycoMimetics could still turn things around. The small cap has another shot on goal with Phase III AML candidate uproleselan and $184.2 million in cash to get it to the compound's next readout by YE20.

After hours Friday,

Read the full 559 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers